Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

alogliptin

Known as: Benzonitrile, 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)- pyrimidinyl]methyl]-, 2-((6-((3R)-3-aminopiperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)methyl) benzonitrile, Alogliptinum 
A selective, orally bioavailable, pyrimidinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. In addition to its… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND The EXAMINE trial showed non-inferiority of the DPP-4 inhibitor alogliptin to placebo on major adverse cardiac event… 
Review
2014
Review
2014
Type 2 diabetes mellitus (T2DM) is characterized by a progressive failure of pancreatic β-cell function (BCF) with insulin… 
  • table 4
Highly Cited
2013
Highly Cited
2013
BACKGROUND To assess potentially elevated cardiovascular risk related to new antihyperglycemic drugs in patients with type 2… 
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Highly Cited
2011
Highly Cited
2011
Dipeptidyl peptidase-4 (DPP-4 or CD26) inhibitors, a new class of antidiabetic compounds, are effective in the treatment of… 
Highly Cited
2009
Highly Cited
2009
Aims: To assess the efficacy and safety of alogliptin added to insulin in patients with type 2 diabetes inadequately controlled… 
Highly Cited
2009
Highly Cited
2009
OBJECTIVES: To compare the efficacy and safety of alogliptin, a dipeptidyl peptidase‐4 (DPP‐4) enzyme inhibitor, in elderly (≥65… 
Highly Cited
2009
Highly Cited
2009
ABSTRACT Objectives: To evaluate the efficacy and safety of alogliptin in patients with type 2 diabetes inadequately controlled… 
Highly Cited
2009
Highly Cited
2009
Aim:  To evaluate the efficacy and safety of alogliptin, a potent and highly selective dipeptidyl peptidase‐4 (DPP‐4) inhibitor… 
Highly Cited
2008
Highly Cited
2008
OBJECTIVE—To evaluate the dipeptidyl peptidase-4 (DPP-4) inhibitor alogliptin in drug-naïve patients with inadequately… 
  • table 1
Highly Cited
2007
Highly Cited
2007
Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4). Herein, we describe the…